Amgen Inc. (62)

Browse by Contract Category

Contracts

Amendment No. 1 to Sourcing and Supply Agreement, dated July 14, 2022, by and between Amgen USA Inc., a wholly owned subsidiary of Amgen Inc., and DaVita Inc (Filed With SEC on November 4, 2022)
Officers Certificate of the Company, dated as of August 18, 2022, including forms of the Companys 4.050% Senior Notes due 2029, 4.200% Senior Notes due 2033 and 4.875% Senior... (Filed With SEC on August 18, 2022)
Agreement and Plan of Merger, dated as of August 3, 2022 among ChemoCentryx, Inc., Amgen Inc. and Carnation Merger Sub, Inc (Filed With SEC on August 4, 2022)
Amgen Inc. Executive Incentive Plan (Filed With SEC on April 28, 2022)
Form of ASR Agreement (Filed With SEC on February 25, 2022)
Underwriting Agreement, dated August 15, 2022, by and among the Company and BofA Securities, Inc., Morgan Stanley & Co. LLC, Credit Suisse Securities (USA) LLC and Deutsche Bank... (Filed With SEC on August 18, 2022)
First Amendment to Collaboration Agreement, dated April 20, 2022, by and between Amgen Inc. and BeiGene Switzerland GmbH, and BeiGene, Ltd (Filed With SEC on August 5, 2022)
Officers Certificate of the Company, dated as of February 22, 2022, including forms of the Companys 3.000% Senior Notes due 2029, 3.350% Senior Notes due 2032, 4.200% Senior Notes... (Filed With SEC on February 22, 2022)
Underwriting Agreement, dated February 17, 2022, by and among the Company and BofA Securities, Inc., Morgan Stanley & Co. LLC, Citigroup Global Markets Inc. and Goldman Sachs &... (Filed With SEC on February 22, 2022)
Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended (Filed With SEC on February 16, 2022)
Description of Amgen Inc.s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 16, 2022)
Form of Grant of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended (Filed With SEC on February 16, 2022)
Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended (Filed With SEC on February 16, 2022)
Third Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 20, 2021 (Filed With SEC on February 16, 2022)
Third Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective January 1, 2022 (Filed With SEC on February 16, 2022)
Aircraft Time Sharing Agreement, dated December 3, 2021, by and between Amgen Inc. and Robert A. Bradway (Filed With SEC on February 16, 2022)
Amendment No. 8 to the Collaboration Agreement, dated November 19, 2021, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC (Filed With SEC on February 16, 2022)
Amendment No. 3 to the Exclusive License and Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG (portions of the exhibit have been... (Filed With SEC on January 31, 2022)
Agreement and Plan of Merger, dated July 27, 2021, by and among Amgen Inc., Teneobio, Inc., Tuxedo Merger Sub, Inc., and Fortis Advisors LLC (Filed With SEC on November 3, 2021)
Underwriting Agreement, dated August 5, 2021, by and among the Company and Citigroup Global Markets Inc., Morgan Stanley & Co. LLC, Barclays Capital Inc. and Goldman Sachs & Co.... (Filed With SEC on August 9, 2021)
Officers Certificate of the Company, dated as of August 9, 2021, including forms of the Companys 1.650% Senior Notes due 2028, 2.000% Senior Notes due 2032, 2.800% Senior Notes... (Filed With SEC on August 9, 2021)
Amended and Restated Collaboration Agreement, dated June 2, 2021, by and between Amgen Inc. and Novartis Pharma AG (Filed With SEC on August 4, 2021)
Agreement and Plan of Merger, dated as of March 4, 2021, by and among Amgen Inc., Franklin Acquisition Sub, Inc. and Five Prime Therapeutics, Inc (Filed With SEC on March 4, 2021)
Amendment No. 7 to the Collaboration Agreement, dated December 18, 2020, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC (Filed With SEC on February 9, 2021)
Amgen Inc. 2009 Director Equity Incentive Program. (As Amended (Filed With SEC on February 9, 2021)
Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended on December 1 (Filed With SEC on February 9, 2021)
Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December (Filed With SEC on February 9, 2021)
Form of Grant of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 1 (Filed With SEC on February 9, 2021)
Description of Amgen Inc.s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 9, 2021)
Restated Amendment No. 2 to Share Purchase Agreement, dated September 24, 2020, by and among BeiGene, Ltd. and Amgen Inc (Filed With SEC on October 29, 2020)
Amendment No. 2 to the Collaboration Agreement, dated August 19, 2020, by and between Amgen Inc. and Novartis Pharma AG (Filed With SEC on October 29, 2020)
Registration Rights Agreement, dated as of August 17, 2020, by and among the Company, BofA Securities, Inc. and J.P. Morgan Securities LLC, as lead dealer managers, and BNP... (Filed With SEC on August 18, 2020)
Officers Certificate of Amgen Inc., dated as of August 17, 2020, including forms of the Companys 2.770% Senior Notes due 2053 (Filed With SEC on August 18, 2020)
Amendment Nos. 2 through 6 to the March 30, 2012 Collaboration Agreement between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, dated May 2 and 27 and October 2, 2016,... (Filed With SEC on July 29, 2020)
Officers Certificate of the Company, dated as of May 6, 2020, including the form of the Companys 2.300% Senior Notes due 2031 (Filed With SEC on May 6, 2020)
Underwriting Agreement, dated as of May 4, 2020, by and among the Company and BofA Securities, Inc., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC and Morgan Stanley &... (Filed With SEC on May 6, 2020)
Amendment No. 2 to Share Purchase Agreement, dated March 17, 2020, by and among BeiGene, Ltd. and Amgen Inc (Filed With SEC on May 1, 2020)
Side Letter Regarding Collaboration Agreement and Stivarga Agreement, dated February 13, 2020, by and between Onyx Pharmaceuticals, Inc. and Bayer HealthCare LLC (Filed With SEC on May 1, 2020)
Agreement between Amgen Inc. and Peter Griffith, dated October 18, 2019 (Filed With SEC on May 1, 2020)
Officers Certificate of the Company, dated as of February 21, 2020, including forms of the Companys 1.900% Senior Notes due 2025, 2.200% Senior Notes due 2027, 2.450% Senior Notes... (Filed With SEC on February 21, 2020)
Underwriting Agreement, dated February 18, 2020, by and among the Company and Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, Barclays Capital Inc. and Morgan Stanley &... (Filed With SEC on February 21, 2020)
Description of Amgen Inc.s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 12, 2020)
Form of Grant of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 10, 2019.) (Filed With SEC on February 12, 2020)
Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 10, 2019.) (Filed With SEC on February 12, 2020)
Amendment No. 2 to the Asset Purchase Agreement, dated October 17, 2019, by and between Amgen Inc. and Celgene Corporation (Filed With SEC on February 12, 2020)
Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended on December 10, 2019.) (Filed With SEC on February 12, 2020)
Form of Restricted Stock Unit Agreement for the Amgen Inc. 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.) (Filed With SEC on February 12, 2020)
Amgen Inc. 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.) (Filed With SEC on February 12, 2020)
Guarantee, dated as of October 31, 2019, made by and among BeiGene, Ltd. and Amgen Inc (Filed With SEC on February 12, 2020)
Form of Cash-Settled Restricted Stock Unit Agreement for the Amgen 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.) (Filed With SEC on February 12, 2020)
Second Amendment to the Amgen Inc. Supplemental Retirement Plan (As Amended and Restated effective October 23, 2019) (Filed With SEC on February 12, 2020)
Second Amendment to the Amgen Nonqualified Deferred Compensation Plan (As Amended and Restated effective January 1, 2020) (Filed With SEC on February 12, 2020)
Letter Agreement, dated November 21, 2019, by and between Amgen Inc. and the parties named therein re: Treatment of Certain Product Inventory in connection with Amgens acquisition... (Filed With SEC on February 12, 2020)
Collaboration Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene Switzerland GmbH, a wholly-owned subsidiary of BeiGene, Ltd (Filed With SEC on February 12, 2020)
Second Amended and Restated Credit Agreement, dated as of December 12, 2019, among Amgen Inc., the Banks therein named, Citibank, N.A., as Administrative Agent, and JPMorgan Chase... (Filed With SEC on December 12, 2019)
Amendment No. 1 to the Asset Purchase Agreement, dated August 25, 2019, by and between Amgen Inc. and Celgene Corporation (Filed With SEC on October 18, 2019)
Asset Purchase Agreement, dated August 25, 2019, by and between Amgen Inc. and Celgene Corporation (Filed With SEC on August 26, 2019)
Irrevocable Guarantee, dated August 25, 2019, by and between Amgen Inc. and Bristol-Myers Squibb Company (Filed With SEC on August 26, 2019)
Letter Agreement, dated June 25, 2019, by and between Amgen Inc. and UCB Celltech (portions of the exhibit have been omitted because they are both (i) not material and (ii) would... (Filed With SEC on July 31, 2019)
Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 7, 2018.) (Filed With SEC on February 13, 2019)
Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended on December 7, 2018.) (Filed With SEC on February 13, 2019)
Form of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 7, 2018.) (Filed With SEC on February 13, 2019)